The treatment of type 2 diabetes patients with bromocriptine-QR, a unique, quick release
micronized formulation of bromocriptine, improves glycemic control and reduces adverse …

Objective: The objective of the present study was to evaluate the effect of bromocriptine on
cardiovascular complications associated with type-2 diabetes mellitus (DM). Materials and …

Abstract Food and Drug Administration (FDA) approved bromocriptine mesylate, a quick
release formulation, 0.8 mg tablets, as an adjunct to diet and exercise to improve glycemic …

Bromocriptine-QR is a sympatholytic dopamine D2 agonist for the treatment of type 2
diabetes that has demonstrated rapid (within 1 year) substantial reductions in adverse …

Bromocriptine, an antinociceptive D2 receptor agonist, is thought to reorganize an
excessively heightened hypothalamic drive for higher fatty acids, plasma glucose, and tri …

A placebo‐controlled prospective safety study of quick‐release bromocriptine in patients
with type 2 diabetes has shown a 40% reduction in cardiovascular events. Possible …

Bromocriptine mesylate quick-release was approved by the Food and Drug Administration
(FDA) in May 2009, for the treatment of type 2 diabetes. Bromocriptine is thought to act on …

Bromocriptine (BC), a sympatholytic dopaminergic D2 receptor agonist, has been
comprehensively used in clinic to treat Parkinson's disease (PD) and prolactinomas …

Abstract Background Type 2 diabetes (T2DM) patients, including those in good glycemic
control, have an increased risk of cardiovascular disease (CVD). Maintaining good glycemic …

A quick-release formulation of bromocriptine is the latest drug approved by the US Food and
Drug Administration for the treatment of type 2 diabetes mellitus. Most interestingly, the …